Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ENTR-601-44 · 2 trials · 1 indication
Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.
Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.
| Arm | Type | Description |
|---|---|---|
| ENTR-601-44 | EXPERIMENTAL | ENTR-601-44 intravenous infusion every 6 weeks |
| ENTR-601-45 | EXPERIMENTAL | ENTR-601-45 intravenous infusion every 6 weeks |
| Placebo | PLACEBO_COMPARATOR | intravenous infusion every 6 weeks |
| Name | Type | Description |
|---|---|---|
| ENTR-601-44 | DRUG | ENTR-601-44 intravenous infusion |
| ENTR-601-45 | DRUG | ENTR-601-45 intravenous infusion |
| ENTR-601-44 - matching placebo | DRUG | intravenous infusion |
Inclusion Criteria: * Willing and able to provide consent (if at age of majority) or assent (if a minor) * Participant completed clinical study ENTR-601-44-201 or ENTR-601-45-201 * Males who are sexually active with a female partner of childbearing potential must agree to use condoms during sexual ...
ENTR-601-44 is an investigational small molecule developed by Entrada Therapeutics for Duchenne Muscular Dystrophy (DMD). It is designed for patients whose disease is amenable to exon 44 skipping. The drug is in Phase 2 clinical development and has received a Rare Pediatric Disease designation from the FDA.
ENTR-601-44 is being developed to treat Duchenne Muscular Dystrophy in patients whose genetic mutation is amenable to exon 44 skipping. DMD is a neuromuscular condition, and this therapy targets the specific exon 44 mutation subset of the patient population.
ENTR-601-44 targets DMD exon 44. By directing the drug at exon 44, the therapy is intended for Duchenne Muscular Dystrophy patients with mutations amenable to exon 44 skipping. It is a small molecule developed using Entrada Therapeutics' Endosomal Escape Vehicle platform.
ENTR-601-44 is being developed by Entrada Therapeutics, Inc., which trades on the Nasdaq under the ticker TRDA. The company is advancing the candidate for Duchenne Muscular Dystrophy patients amenable to exon 44 skipping.
ENTR-601-44 is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. The program includes a Phase 2 long-term extension study and a Phase 1 study, both of which are active.
ENTR-601-44 is being evaluated in two clinical trials. NCT07037862 is a Phase 1 study in participants with Duchenne Muscular Dystrophy amenable to exon 44 skipping, and it is currently recruiting. NCT07682129 is a Phase 2 long-term extension study, ELEVATE-LTE, that is not yet recruiting.